skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Abstract

Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs’ overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.

Authors:
 [1];  [2];  [3];  [2];  [1]
  1. Massachusetts General Hospital, Department of Radiology (United States)
  2. Massachusetts General Hospital Cancer Center (United States)
  3. New England Cancer Care Specialists (United States)
Publication Date:
OSTI Identifier:
22749739
Resource Type:
Journal Article
Journal Name:
Cardiovascular and Interventional Radiology
Additional Journal Information:
Journal Volume: 41; Journal Issue: 11; Other Information: Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0174-1551
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; HEPATOMAS; PATIENTS; RADIOEMBOLIZATION; YTTRIUM 90

Citation Formats

Wehrenberg-Klee, Eric, Goyal, Lipika, Dugan, Matthew, Zhu, Andrew X., and Ganguli, Suvranu. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. United States: N. p., 2018. Web. doi:10.1007/S00270-018-1993-1.
Wehrenberg-Klee, Eric, Goyal, Lipika, Dugan, Matthew, Zhu, Andrew X., & Ganguli, Suvranu. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. United States. doi:10.1007/S00270-018-1993-1.
Wehrenberg-Klee, Eric, Goyal, Lipika, Dugan, Matthew, Zhu, Andrew X., and Ganguli, Suvranu. Thu . "Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma". United States. doi:10.1007/S00270-018-1993-1.
@article{osti_22749739,
title = {Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma},
author = {Wehrenberg-Klee, Eric and Goyal, Lipika and Dugan, Matthew and Zhu, Andrew X. and Ganguli, Suvranu},
abstractNote = {Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs’ overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.},
doi = {10.1007/S00270-018-1993-1},
journal = {Cardiovascular and Interventional Radiology},
issn = {0174-1551},
number = 11,
volume = 41,
place = {United States},
year = {2018},
month = {11}
}